New study aims to predict clot risk in PCOS patients
NCT ID NCT07571096
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study is creating a risk assessment system to predict blood clotting abnormalities in women with polycystic ovary syndrome (PCOS). Researchers will analyze hormone, metabolic, and genetic factors in 100 participants aged 14 to 45. The goal is to help doctors personalize care and prevent complications.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a risk assessment tool to help doctors identify which women with PCOS are at higher risk for blood clotting problems, enabling earlier and more personalized care.
- What could go wrong
- This is an early observational study with only 100 participants, so the findings may not apply to all women with PCOS. The model needs further validation before it can be used in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Female participants aged 14 to 45 years with polycystic ovary syndrome will be enrolled. Participants will be classified according to the presence or absence of decreased protein C and/or protein S levels.
- Ages
-
14 to 45 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female participants aged 14 to 45 years * Diagnosis of polycystic ovary syndrome (PCOS) * For adult participants, PCOS diagnosed according to the 2023 international evidence-based guideline. After exclusion of related disorders, diagnosis is based on ovulatory dysfunction and/or irregular menstrual cycles together with clinical hyperandrogenism, biochemical hyperandrogenism, or polycystic ovarian morphology on ultrasound where appropriate * For adolescent participants, PCOS diagnosed according to adolescent-specific recommendations. After exclusion of related disorders, both ovulatory dysfunction and/or irregular menstrual cycles and clinical or biochemical hyperandrogenism are required * Irregular menstrual cycles are defined as follows: more than 1 year and less than 3 years after menarche, menstrual cycles shorter than 21 days or longer than 45 days; more than 3 years after menarche to perimenopause, menstrual cycles shorter than 21 days or longer than 35 days, or fewer than 8 cycles per year; any cycle longer than 90 days more than 1 year after menarche; or primary amenorrhea by age 15 years or more than 3 years after thelarche * No use within 3 months before blood sampling of anticoagulant drugs, procoagulant drugs, oral contraceptives, or other medications that may affect sex hormones, insulin, glucose metabolism, or coagulation function Exclusion Criteria: * Confirmed pregnancy * Hematologic disease * History of malignant tumor * Use of medications within 12 weeks before enrollment that may interfere with study assessments * Disorders that may cause hyperandrogenism or ovulatory dysfunction, including congenital adrenal hyperplasia, Cushing syndrome, functional hypothalamic amenorrhea, thyroid disease, hyperprolactinemia, or primary ovarian insufficiency * Disorders that may affect protein C or protein S levels, including antiphospholipid syndrome, liver disease, or tumor-related conditions * In adolescents, polycystic ovarian morphology alone will not be used to establish the diagnosis of PCOS
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Polycystic ovary syndrome (PCOS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Guangdong Women and Children Hospital
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own blood plasma kickstart ovulation in PCOS?
- Could a pancreatic peptide hold clues to PCOS-Related insulin resistance?
- PCOS may fuel fatty liver in teens even after accounting for obesity — a study investigates
- Mind over menstrual pain: could a Four-Week online program ease PCOS symptoms?
- Sugar-Alcohol combo may restore periods in PCOS
- Could a diabetes drug boost pregnancy success in women with PCOS?